Tetrahedron Letters 51 (2010) 3205-3207

Contents lists available at ScienceDirect

Tetrahedron Letters

journal homepage: www.elsevier.com/locate/tetlet



Staudinger and retro-Staudinger reactions. The dichloro- β -lactam moiety as a useful handle for the synthesis of 4-aryl-2*H*-1,3-benzothiazine 1,1-dioxides

Lajos Fodor^{a,b,*}, Péter Csomós^{a,b}, Antal Csámpai^c, Pál Sohár^{c,d,*}

^a Institute of Pharmaceutical Chemistry, University of Szeged, and Research Group of Stereochemistry of the Hungarian Academy of Sciences, H-6720, Szeged, Eötvös u. 6., Hungary ^b Central Laboratory, County Hospital, H-5701 Gyula, POB 46, Hungary

^c Institute of Chemistry, Eötvös Loránd University, Hungary

^d Protein Modelling Research Group, Hungarian Academy of Sciences and Eötvös Loránd University, H-1518 Budapest, POB 32, Hungary

ARTICLE INFO

Article history: Received 13 January 2010 Revised 22 March 2010 Accepted 12 April 2010 Available online 18 April 2010

Keywords: 1,3-Benzothiazine Dichloro-β-lactam Staudinger reaction Oxidation

ABSTRACT

The dichloro- β -lactam ring, obtained via Staudinger reaction of 4-aryl-2*H*-1,3-benzothiazines, proved to be a useful protecting strategy for the synthesis of 4-aryl-2*H*-1,3-benzothiazine 1,1-dioxides. After oxidation of the 1,1-dichloroazeto[2,1-*c*][1,3]-benzothiazin-2-ones, the thiazine ring could be recovered selectively and in good yield by treatment with base. Thus, novel 4-aryl-2*H*-1,3-benzothiazine 1,1-dioxides were obtained efficiently.

© 2010 Elsevier Ltd. All rights reserved.

Among condensed sulfur–nitrogen heterocycles, sulfones such as 1,4-benzothiazepine 1,1-dioxides exhibit a broad range of biological activity (antiatherosclerotic,¹ antihyperlipidaemic,² muscle relaxation accelerator³ and antiarrhythmic effects⁴). The six-membered homologues, 1,4-benzothiazine 1,1-dioxides, inhibit peptide deformylase, for example,⁵ while 1,2-benzothiazine 1,1-dioxides include 'oxicam' drugs such as meloxicam and piroxicam.⁶ In contrast, the 1,3-benzothiazine 1,1-dioxide ring system has been prepared in a few cases through ring-enlargement reactions of substituted saccharin derivatives.⁷ (It is noteworthy that this method is only suitable for the synthesis of dihydro- or 4-oxo-1,3-benzothiazine sulfones.) This stems from the synthetic difficulties encountered during conventional procedures; the oxidation of various 1,3-benzothiazines results in a ring-contraction reaction, providing 1,2-benzoisothiazoles as products.⁸

As part of a programme aimed at investigations of different condensed *S*,*N*-heterocycles, including β -lactam-condensed derivatives,^{9a} we wanted to devise a procedure for the preparation of potentially pharmacologically active 2*H*-1,3-benzothiazine sulfones **6a–c** (Scheme 1).

We previously studied the reactions of monochloro-, dichloroand aryl-substituted β -lactam-condensed benzothiazines. Under basic conditions, several ring-enlargement reactions occurred. Thus, 1,4-^{9b,c} and 4,1-benzothiazepines,^{9d} isoquinolines^{9e} and thiazoles^{9e} were obtained. In the course of our present investigations, we prepared angularly-condensed dichloro- β -lactams **3a–c** by Staudinger reaction¹⁰ of 4-aryl-benzothiazines **1a–c**.¹¹ Surprisingly, on treatment with sodium methoxide in methanol at reflux, the latter β -lactams did not display the expected reactivity (ring enlargement,^{9b–e} ester formation¹² or chloro-methoxy exchange¹³). Instead, the starting 1,3-benzothiazines **1a–c** were recovered, almost quantitatively, via retro-Staudinger reaction.¹⁴

This observation led us to examine the use of the dichloro- β lactam moiety as a protecting strategy for the synthesis of sulfones **6a–c**, which we could not obtain earlier by the direct oxidation of benzothiazines 1a-c. As an example, treatment of 6,7-dimethoxy-1.3-benzothiazines **1a-c** with peracetic acid furnished 1.2-benzothiazoles 2a-c instead of the expected sulfone products 6a-c (Scheme 1).⁸ For the oxidation of β -lactam-condensed 1,3-thiazines **3a-c**, peroxyacetic acid proved to be a mild and efficient reagent, and azetothiazine sulfones **4a–c** were obtained selectively in good yields.¹⁵ In this oxidation reaction the dichloro-β-lactam moiety protected the benzothiazine ring from undergoing ring-contraction. Treatment of **4a-c** with a refluxing solution of sodium methoxide provided the novel target sulfones **6a-c**, most probably via **5a–c** as intermediates.¹⁴ The Staudinger reactions of **6a–c** with dichloroacetyl chloride in refluxing toluene afforded *β*-lactams 4a-c (Scheme 1).¹¹

The structures of the new compounds were confirmed by IR and NMR spectroscopy. 11,14,15



^{*} Corresponding authors. Tel.: +36 66 463763; fax: +36 66 526539 (L.F.); tel.: +36 1 3722911; fax: +36 1 3722592 (P.S.).

E-mail addresses: fodor@pandy.hu (L. Fodor), sohar@chem.elte.hu (P. Sohár).

^{0040-4039/\$ -} see front matter @ 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.tetlet.2010.04.051



a: R = H; **b**: R = Cl; **c**: R = Me

Scheme 1. Reagents and conditions: (i) Cl₂CHCOCI, Et₃N, toluene, reflux, 1 h; (ii) NaOMe, MeOH, reflux, 15 min; (iii) MeC(O)OOH, MeCOOH, rt, 1 d.

The presence of a β -lactam ring was proved by the IR frequency (1785–1808 cm⁻¹) which is higher than expected^{16a} for condensed azetidinones, due to the electron-withdrawing effect of the neighbouring CCl₂ group.

The oxidation to sulfones (products **4** and **6**) follows from the appearance of a stretching IR band-pair due to the SO₂ group at frequencies in accord with literature data,^{16b} and the significant shifts in the ¹H and ¹³C NMR spectra of the neighbouring methylene group (by ~20 and 27.5 ppm in the ¹³C NMR spectra of **4** and **6**), and of the H-6 proton (7.39–7.55 ppm) relative to the values measured for **3a,b** (6.69 and 6.67 ppm). A similar shift was observed for the C-5a resonance (from 122.8 ± 0.1 ppm to 131.4 ± 0.1 ppm). As a consequence of the molecular symmetry, the CH₂ resonances occur as singlets in derivatives of type **6**, and as two doublets for the other compounds investigated.

The singlet due to the methylene protons was shifted downfield in **4a–c** relative to **3b,c** (by 0.06 ppm) due to the -I effect of the sulfone group in the *para* position, while products **6a–c** exhibited opposite shifts (by 0.20 ppm). This phenomenon can be explained by the compensating (electron-releasing) effect of the nitrogen atom (of electron-reservoir character) in the contiguous conjugated bond chain.

In summary, we have developed a new procedure for the preparation of 4-aryl-2*H*-1,3-benzothiazine 1,1-dioxides **6a–c**. Staudinger reaction of the substrate 4-aryl-2*H*-1,3-benzothiazines **1a–c** results in efficient formation of the dichloro- β -lactam subunit which can be removed on treatment with sodium methoxide in methanol following oxidation. This appears to be the first report of a retro-Staudinger reaction. To the best of our knowledge, no protecting group is available for imines from which they can be subsequently recovered.¹⁷ Further investigations are in progress to extend the applicability of the dichloro- β -lactam moiety as a protecting group.

Acknowledgements

The authors express their thanks to the Hungarian Scientific Research Foundation (OTKA) for financial support. We are indebted to Mrs. E. Juhász Dinyáné for technical assistance.

References and notes

- 1. Brieaddy, L. E. WO Patent 9316055, 1993; Chem. Abstr. 1994, 120, 164244.
- (a) Brieaddy, L. E. WO Patent 9605188, 1996; *Chem. Abstr.* **1996**, *125*, 114724.;
 (b) Sasahara, T.; Mohri, M. WO Patent 2004/020421, 2004; *Chem. Abstr.* **2004**, *140*, 253584.;
 (c) Starke, I.; Alenfalk, S.; Nordberh, M. P.; Dahlstrom, M. U. J.; Bostrom, S. J.; Lemurell, M. A.; Wallberg, A. C. WO Patent 2004076430, 2004; *Chem. Abstr.* **2004**, *141*, 260784.
- 3. Kaneko, N. WO Patent 2005105793, 2005; Chem. Abstr. 2005, 143, 452896.
- Marks, A. R.; Landry, D. W.; Deng, S.; Cheng, Z. Z.; Lehnart, S. E. WO Patent 2007024717, 2007; Chem. Abstr. 2007, 146, 295964.
- Cali, P.; Hjelmencrantz, A.; Naerum, L. WO Patent 2005092872, 2005; Chem. Abstr. 2005, 143, 367310.
- Richy, F.; Scarpignato, C.; Lanas, A.; Reginster, J.-Y. Pharmacol. Res. 2009, 60, 254.
- (a) Zinnes, H.; Comes, R. A.; Shavel, J. J. Org. Chem. **1964**, 29, 2068; (b) Elghamry, I.; Döpp, D. Tetrahedron Lett. **2001**, 42, 5651; (c) Elghamry, I.; Döpp, D.; Henkel, G. J. Heterocycl. Chem. **2007**, 44, 849.
- Szabó, J.; Szücs, E.; Fodor, L.; Katócs, Á.; Bernáth, G.; Sohár, P. Tetrahedron 1988, 44, 2985.
- (a) Fodor, L.; Szabó, J.; Sohár, P. Tetrahedron 1981, 37, 963; (b) Fodor, L.; Szabó, J.; Bernáth, G.; Párkányi, L.; Sohár, P. Tetrahedron Lett. 1981, 22, 5077; (c) Fodor, L.; Szabó, J.; Szücs, E.; Bernáth, G.; Sohár, P.; Tamás, J. Tetrahedron 1984, 40, 4089; (d) Csomós, P.; Fodor, L.; Bernáth, G.; Sinkkonen, J.; Salminen, J.; Wiinamäki, K.; Pihlaja, K. Tetrahedron 2008, 64, 1002; (e) Fodor, L.; Szabó, J.; Bernáth, G.; Sohár, P.; Argay, G.; Kálmán, A.; Tamás, J. Tetrahedron 1988, 44, 7180.
- (a) Cossío, F. P.; Arrieta, A.; Sierra, M. A. Acc. Chem. Res. 2008, 41, 925;
 (b) Xu, J. Arkivoc 2009, ix, 21; (c) Fu, N.; Tidwell, T. T. Tetrahedron 2008, 64, 10465.
- 11. General procedure for azetobenzothiazines (3a-c and 4a-c). To a stirred solution of the 4H-1,3-benzothiazine derivative (1a-c or 6a-c) (2.0 mmol) in anhydrous toluene (10 ml), dichloroacetyl chloride (3.0 mmol) was added. The solution was heated at reflux and Et₃N (0.4 mL, 3.0 mmol) in anhydrous toluene (20 mL) was added dropwise over 1 h. The reaction mixture was then cooled and filtered and the residual triethylammonium chloride was washed with toluene. The organic layer was washed with brine (20 mL) and dried over Na₂SO₄. After evaporation, the oily residue crystallized on trituration with EtOH. Analytical data for 3a were identical to those reported earlier.^{9a} Compound 3b: white crystalline powder, mp 217-219 °C (from EtOH), yield 95%. v_{max} (KBr disc) T788 (ν=0), 1262 (νC-0), 866 (γC_{Ar}H, condensed benzene ring), 780 (γC_{Ar}H, *para*-disubstituted ring), 677 (CCl₂) cm⁻¹. ¹H NMR δ (500 MHz, CDCl₃): 7.45 (2H, m, H-2',6'), 7.39 (2H, m, H-3',5'), 7.15 (1H, s, H-9), 6.69 (1H, s, H-6), 5.00 (1H, d, J = 12.1 Hz, SCH₂), 4.44 (1H, d, J = 12.1 Hz, SCH₂), 3.98 (3H, s, 8–OCH₃), 3.88 (3H, s, 7–OCH₃) ppm; ¹³C NMR δ (125 MHz, CDCl₃): 160.4 (C=O), 150.2 (C-7), 146.9 (C-8), 135.9 (C-4'), 135.1 (C-1'), 130.1 (C-2'), 129.1 (C-3'), 122.9 (C-5a), 122.0 (C-9a), 114.7 (C-9), 111.1 (C-6), 90.4 (C-1), 73.7 (C-9b), 38.1 (CH₂) ppm. Anal. Calcd for C₁₈H₁₄Cl₃NO₃S (430.73): C, 50.19; H, 3.28; N, 3.25; S, 7.44. Found: C, 50.35; H, 3.52; N, 3.01; S, 7.68. Compound 3c: white crystalline powder, mp 186–188 °C (from EtOH), yield 96%. v_{max} (KBr disc) 1785 (vC=O),

1253 (νC–O), 867 (γC_{Ar}H, condensed benzene ring), 778 (γC_{Ar}H, paradisubstituted ring), 679 (CCl₂) cm⁻¹. ¹H NMR δ (500 MHz, CDCl₃): 7.40 (2H, m, H-2',6'), 7.23 (2H, m, H-3',5'), 7.17 (1H, s, H-9), 6.67 (1H, s, H-6), 5.00 (1H, d, J = 12.1 Hz, SCH₂), 4.46 (1H, d, J = 12.1 Hz, SCH₂), 3.98 (3H, s, 8-OCH₃), 3.88 (3H, s, 7-OCH₃), 2.38 (3H, s, CH₃) ppm; ¹³C NMR δ (125 MHz, CDCl₃): 160.5 (C=O), 150.0 (C-7), 146.7 (C-8), 139.7 (C-4'), 133.3 (C-1'), 129.6 (C-3'), 128.7 (C-2'), 122.7 (C-5a), 122.2 (C-9a), 115.0 (C-9), 110.8 (C-6), 90.6 (C-1), 74.0 (C-9b), 37.9 (CH₂) ppm. Anal. Calcd for C₁₉H₁₇Cl₂NO₃S (410.31): C, 55.62; H, 4.18; N, 3.41; S, 7.82. Found: C, 55.78; H, 4.01; N, 3.63; S, 8.08. Compounds **4a**–c: the analytical data were identical to those reported.¹⁴ Yields, **4a**: 97%, **4b**: 95%, **4c**: 88%.

- (a) Alcaide, B.; Almendros, P.; Aragoncillo, C. *Chem. Rev.* 2007, *107*, 4437; (b) Alcaide, B.; Almendros, P.; Redondo, M. *Chem. Commun.* 2006, 2616; (c) Alcaide, B.; Aly, M.; Rodríguez, C.; Rodríguez-Vicente, A. *J. Org. Chem.* 2000, *65*, 3453.
 Dejaegher, Y.; Mangelinkx, P.; De Kimpe, N. *J. Org. Chem.* 2002, *67*, 2075.
- General procedure for the retro-Staudinger reaction of 3a-c and 4a-c. Preparation of 1a-c and 6a-c. Azeto-1,3-thiazine 3a-c or 4a-c (0.66 mmol) was dissolved in dry MeOH (40 mL). To this stirred solution, NaOMe (71 mg, 1.32 mmol) was added. The reaction mixture was stirred at reflux for 15 min. After evaporation, the residue was dissolved in CH2Cl2 (20 mL). The organic phase was extracted with H₂O (10 mL), dried (Na₂SO₄) and evaporated. Compounds 1a-c are known.¹⁸ The atom numbering of compounds 3 and 4 was also used for products 6. Compound 6a: white crystalline powder, mp 197-198 °C (from EtOH), yield 94%. v_{max} (KBr disc) 1300 (v_{as}SO₂), 1264 (vC-O), 1126 (v_sSO₂), 851 ($\gamma C_{Ar}H$, condensed benzene ring), 778 ($\gamma C_{Ar}H$, monosubstituted ring), 688 ($\gamma C_{Ar}C_{Ar}$, monosubstituted ring) cm⁻¹. ¹H NMR δ (500 MHz, CDCl₃): 7.64 (2H, m, H-2',6'), 7.55 (1H, s, H-6), 7.54 (1H, m, H-4'), 7.49 (2H, m, H-3',5'), 6.86 (1H, s, H-9), 5.10 (2H, s, SCH₂), 4.05 (3H, s, 7-OCH₃), 3.78 (3H, s, 8-OCH₃) ppm; ¹³C NMR δ (125 MHz, CDCl₃): 166.9 (C-9b), 152.5 (C-8),* 152.4 (C-7),* 138.3 (C-1'), 131.4 (C-5a), 131.1 (C-4'), 129.4 (C-2'), 128.9 (C-3'), 123.8 (C-9a), 113.5 (C-10), 105.2 (C-6), 66.6 (CH₂) ppm, * reversed assignments are also possible. Anal. Calcd for C₁₆H₁₅NO₄S (317.36): C, 60.55; H, 4.76; N, 4.41; S, 10.10. Found: C, 60.39; H, 5.01; N, 4.23; S, 10.31. Compound 6b: white crystalline powder, mp 232–233 °C (from EtOH), yield 93%. v_{max} (KBr disc) 1304 (v_{as}SO₂), 1277 (vC–O), 1124 (v_sSO_2), 877 ($\gamma C_{Ar}H$, condensed benzene ring), 849 ($\gamma C_{Ar}H$, para-disubstituted ring) cm⁻¹. ¹H NMR δ (500 MHz, CDCl₃): 7.59 (2H, m, H-2',6'), (3H, s, H-6), 7.46 (2H, m, H-3',5'), 6.81 (1H, s, H-9), 5.07 (2H, s, SCH₂), 4.03 (3H, s, 7-OCH₃), 3.79 (3H, s, 8-OCH₃) ppm; ¹³C NMR δ (125 MHz, CDCl₃): 165.8 (C-9b), 152.6 (C-7), 152.5 (C-8), 137.4 (C-4'), 136.6 (C-1'), 131.5 (C-5a), 130.8 (C-2'), 129.2 (C-3'), 123.4 (C-9a), 113.1 (C-9), 105.3 (C-6), 66.6 (CH₂) ppm. Anal. Calcd for C16H14CINO4S (351.81): C, 54.62; H, 4.01; N, 3.98; S, 9.11. Found: C, 54.81; H, 3.78; N, 4.13; S, 9.37. Compound 6c: white crystalline powder, mp 214-215 °C (from EtOH), yield 92%. v_{max} (KBr disc) 1302 (v_{as}SO₂), 1277 (vC-O), 1124 (v_sSO_2), 875 (γ_{CArH} , condensed benzene ring), 829 (γ_{CArH} , para-disubstituted ring) cm⁻¹. ¹H NMR δ (500 MHz, CDCl₃): 7.52 (1H, s, H-6).* 7.51 (2H, m, H-2',6'),* 7.27 (2H, m, H-3',5'), 6.89 (1H, s, H-9), 5.06 (2H, s, SCH₂), 4.02 (3H, s, 7-OCH₃), 3.77 (3H, s, 8-OCH₃), 2.43 (3H, s, CH₃) ppm, * reversed assignments are also possible; ¹³C NMR δ (125 MHz, CDCl₃): 166.8 (C-9b), 152.36 (C-8),** 152.32 (C-7),** 141.4 (C-4'), 135.4 (C-1'), 131.4 (C-5a), 129.6 (C-3'), 129.4 (C-2'), 123.9 (C-9a), 113.6 (C-9), 105.2 (C-6), 66.6 (CH₂), 21.8 (CH₃)

ppm, ** reversed assignments are also possible. Anal. Calcd for $C_{17}H_{17}NO_4S$ (331.39): C, 61.61; H, 5.17; N, 4.23; S, 9.68. Found: C, 61.46; H, 5.33; N, 4.01; S, 9.87.

- 15. General procedure for the oxidation of 3a-c. Preparation of 4a-c. Compounds **3a-c** (1.0 g) were suspended in AcOH (10 mL), followed by the addition of freshly prepared peroxyacetic acid¹⁸ (15 mL). After complete dissolution, the reaction mixture was allowed to stand at room temperature for 1 d and then poured onto ice (30 g). The crystals that separated were removed by filtration, and washed with cold H₂O (5 mL) and MeOH (5 mL). Compound 4a: white crystalline powder, mp 160-161 °C (from EtOH), yield 98%. v_{max} (KBr disc) 1808 (vC=O), 1316 (v_{as}SO₂), 1268 (vC-O), 1138 (v_sSO₂), 841 (γC_{Ar}H, condensed benzene ring), 750 ($\gamma C_{Ar}H$, monosubstituted ring), 691 ($\gamma C_{Ar}C_{Ar}$, monosubstituted ring), 679 (CCl₂) cm⁻¹. ¹H NMR δ (500 MHz, CDCl₃): 7.52 (2H, m, H-2',6'), 7.47 (2H, m, H-3',5')*, 7.47 (1H, m, H-4')*, 7.41 (1H, s, H-6), 7.07 (1H, s, H-9), 5.30 (1H, d, J = 13.8 Hz, SCH₂), 4.55 (1H, d, J = 13.8 Hz, SCH₂), 4.04 (3H, s, 8-OCH₃), 3.99 (3H, s, 7-OCH₃) ppm, * two overlapping signals; 13 C NMR δ (125 MHz, CDCl₃): 159.6 (C=O), 151.8 (C-8), 151.0 (C-7), 134.1 (C-1'), 131.4 (C-5a), 130.5 (C-4'), 129.3 (C-3'), 128.8 (C-2'), 126.8 (C-9a), 112.9 (C-9), 106.3 (C-6), 91.5 (C-1), 74.6 (C-9b), 59.2 (CH₂) ppm. Anal. Calcd for C₁₈H₁₅Cl₂NO₅S (428.29): C, 50.48; H, 3.53; N, 3.27; S, 7.49. Found: C, 50.36; H, 3.77; N, 3.42; S, 7.62. Compound 4b: white crystalline powder, mp 118-120 °C (from EtOH), yield 94%. v_{max} (KBr disc) 1803 (vC=O), 1320 (v_{as}SO₂), 1262 (vC-O), 1140 (v_sSO₂), 838 (γ C_{Ar}H, condensed benzene ring), 818 (γ C_{Ar}H, para-disubstituted ring), 669 (CCl₂) cm⁻¹. ¹H NMR δ (500 MHz, CDCl₃): 7.44 (2H, m, H-2',6')*, 7.44 (2H, m, H-3',5')*, 7.40 (1H, s, H-6), 6.98 (1H, s, H-9), 5.27 (1H, d, J = 13.8 Hz, SCH₂), 4.49 (1H, d, J = 13.8 Hz, SCH₂), 4.04 (3H, s, 8-0CH₃), 389 (3H, s, 7-0CH₃) ppm, * two overlapping signals; ¹³C NMR δ (125 MHz, CDCl₃): 159.4 (C=O), 151.9 (C-8), 151.1 (C-7), 136.9 (C-4'), 132.6 (C-1'), 131.3 (C-5a), 130.2 (C-2') 129.5 (C-3'), 126.2 (C-9a), 112.6 (C-9), 106.4 (C-6), 91.4 (C-1), 74.1 (C-9b), 59.0 (CH₂) ppm. Anal. Calcd for C₁₈H₁₄Cl₃NO₅S (462.73): C, 46.72; H, 3.05; N, 3.03; S, 6.93. Found: C, 46.97; H, 3.28; N, 3.19; S, 7.16; Compound 4c: white crystalline powder, mp 220–221 °C (from EtOH), yield 97%. v_{max} (KBr disc) 1802 (vC=O), 1317 ($v_{as}SO_2$), 1264 (vC-O), 1137 (v_sSO_2), 841 ($\gamma C_{Ar}H$, condensed benzene ring), 814 ($\gamma C_{Ar}H$, para-disubstituted ring), 670 (CCl₂) cm⁻¹. ¹H NMR δ (500 MHz, CDCl3): 7.39 (1H, s, H-6), 7.37 (2H, m, H-2',6'), 7.25 (2H, m, H-3',5'), 7.03 (1H, s, H-9), 5.26 (1H, d, J = 13.8 Hz, SCH₂), 4.50 (1H, d, J = 13.8 Hz, SCH₂), 4.04 (3H, s, 8-OCH₃), 3.98 (3H, s, 7-OCH₃), 2.39 (3H, s, CH₃) ppm; ¹³C NMR δ (125 MHz, CDCl₃): 159.6 (C=O), 151.7 (C-8), 150.9 (C-7), 140.8 (C-4'), 131.4 (C-5a), 130.9 (C-1'), 130.0 (C-3'), 128.8 (C-2'), 127.0 (C-9a), 112.9 (C-9), 106.3 (C-6), 91.6 (C-1), 74.5 (C-9b), 59.1 (CH₂), 21.5 (CH₃) ppm. Anal. Calcd for C19H17Cl2NO5S (442.31): C, 51.59; H, 3.87; N, 3.17; S, 7.25. Found: C, 51.45; H, 4.10; N, 3.41; S, 7.08.
- Holly, S.; Sohár, P. In Theoretical and Technical Introduction to the Series Absorption Spectra in the Infrared Region; Láng, L., Prichard, W. H., Eds.; Akadémiai Kiadó: Budapest, 1975; p 113 (a) p 113; (b) pp 128–129.
- Wuts, P. G. M.; Greene, T. W. Protective Groups in Organic Synthesis; Wiley Interscience: Hoboken, New Jersey, 2007.
- 18. Szabó, J.; Fodor, L.; Szücs, E.; Bernáth, G.; Sohár, P. Pharmazie 1984, 39, 426.